medigraphic.com
ISSN 1025-0298 (Digital)
ISSN 1025-028X (Impreso)

2011, Número 3

<< Anterior Siguiente >>

VacciMonitor 2011; 20 (3)


Aspectos relevantes del uso de Mycobacterium´habana´ como candidato vacunal contra la tuberculosis

Valdés I, Echemendía M, Mederos L, Valdivia JA, Montoro E

Idioma: Español
Referencias bibliográficas: 41
Paginas: 34-39
Archivo PDF: 78.61 Kb.


RESUMEN

La eficacia protectora de la actual vacuna (BCG) contra la tuberculosis, para contrarrestar las formas pulmonares de esta enfermedad y su reactivación, resulta variable o poco eficiente, lo cual impone la búsqueda urgente de nuevas alternativas profilácticas contra esta enfermedad. Basados en las ventajas inmunogénicas que ofrece el uso de vacunas vivas, se han encaminado diferentes estrategias de este tipo empleando mutantes auxotróficos de Mycobacterium tuberculosis, BCG recombinante o micobacterias no tuberculosas. Existen evidencias experimentales acerca de la protección conferida tras la vacunación con cepas vivas, inactivadas o fracciones proteicas de Mycobacterium’habana’ TMC-5135 contra la infección por Mycobacterium tuberculosis. Esta respuesta protectora parece ir aparejada de escasos signos de virulencia en los modelos animales ensayados, lo cual coloca a M.´habana´ dentro de los posibles candidatos vacunales contra la tuberculosis al ajustarse a la condición que impone una vacuna clásica de reproducir la infección y los eventos inmunes que le suceden lo más fielmente posible a como ocurren de manera natural, sin causar extensos daños en el receptor


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ginsberg AM. What’s new in tuberculosis vaccines? Bull World Health Organization 2002;80:483-8.

  2. McMurray DN. Recent progress in the development and testing of vaccines against human tuberculosis. Int J Parasitol 2003;33:547-54.

  3. Laxman S. Meena, Rajni I. Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS 2010;277:2416–27.

  4. Svenson S, Källenius G, Pawlowski A, Hamasur B. Towards new tuberculosis vaccines. Human Vaccines 2010;6:309-17.

  5. Locht C. From Genomic Characterization to Improved BCG. En: Nor NM, Acosta A, Sarmiento ME. The Art & Science of Tuberculosis Vaccine Development. Malaysia: Oxford Fajar Sdn. Bhd; 2010. p. 211-21.

  6. Hernández-Pando R. Nuevas vacunas contra la TB. Rev Salud Pública de México 2007;49(Suppl. 1):211-7.

  7. Singhal N, Bisht D, Joshi B. Immunoprophylaxis of tuberculosis: An update of emerging trends. Arch Immunol Ther Exp 2010;58:97–106.

  8. Kaufmann SHE, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature Medicine 2005;11(4S):S33-44. Disponible en: http:// www.nature.com/nm/journal/v11/n4s/full/nm1221.html 11:33-44.

  9. Baumann S, Eddine AN, Kaufmann SHE. Progress in tuberculosis vaccine development. Curr Opinion Immunol 2006;18:438-48.

  10. Valdivia JA, Suárez R, Echemendía M. Mycobacterium´habana´, probable nueva especie dentro de las especies no clasificadas. Bol Hig Epidemiol 1971;9:65-73.

  11. Valdivia JA. Mycobacterium´habana´: Clinical and epidemiological significance. Ann Soc Belg Med Trop 1973;53:263-6.

  12. Meissner G, Schröder KH. Relationship between Mycobacterium simiae and Mycobacterium´habana´. Am Rev Respir Dis 1975;111:196-200.

  13. Weiszfeiler JG, Karczag E. Synonymy of Mycobacterium simiae Karasseva y cols.1965 and Mycobacterium´habana´ Valdivia y cols.1971. Int J Syst Bacteriol 1976;26:474-7.

  14. Mederos LM, Valdivia JA, Sampere MA, Valero-Guillén PL. Analysis of lipids reveals differences between Mycobacterium ´habana´ and Mycobacterium simiae. Microbiology 1998;144:1181-8.

  15. Gupta HP, Singh NB, Mathur IS, Gupta SK. Mycobacterium´habana´, a new immunogenic strain in experimental tuberculosis of mice. Indian J Exp Biol 1979;17:1190-3.

  16. Raj PP, Srivastava S, Jain SK, Srivastava BS, Srivastava R. Protection by live Mycobacterium´habana´ vaccine against Mycobacterium tuberculosis H37Rv challenge in mice. Indian J Med Res 2003;117:139-45.

  17. Singh NB, Celia TA, Lave RE, Rees RJW, Colston DMJ. Vaccination of mice against Mycobacterium leprae infection. Infect Immun 1989;57:653-5.

  18. Singh NB, Mathur IS, Gupta HP, Srivastava A. A novel immunogenic strain Mycobacterium´habana´ against M. ulcerans (Buruli ulcer) infection in mice. Curr Sci 1981;50:994-6.

  19. Anuradha A, Zehra K, Katiyar JC, Gupta HP, Singh NB. Vaccination of hamster with Mycobacterium´habana´ against Leishmania donovani infection. Curr Scien 1995;69:90-3.

  20. Martín C, Gonzalo-Asensio J. Attenuated Vaccines. En: Nor NM, Acosta A, Sarmiento ME. The Art & Science of Tuberculosis Vaccine Development. 1ra ed. Malaysia: Oxford Fajar Sdn. Bhd. (008974-T); 2010. p. 225-43.

  21. Gupta HP, Singh NB, Mathur IS, Gupta SK. Mycobacterium´habana´, a new immunogenic strain in experimental tuberculosis of mice. Indian J Exp Biol 1979;17:1190-3.

  22. Mederos L, Valdivia JA, Valero-Guillén PL. New variants of polar glycopeptidolipids detected in Mycobacterium simiae, including ‘habana’ strains, as evidenced by electrospray ionization-ion trap-mass spectrometry. J Appl Microbiol 2008;105:602-14.

  23. Mederos L, Valdivia JA, Valero-Guillén PL. Analysis of the structure of mycolic acids of Mycobacterium simiae reveals a particular composition of á-mycolates in strain ´habana´, considered as immunogenic in tuberculosis and leprosy. Microbiology 2007;153:4159-65.

  24. Rao V, Fujiwara N, Porcelli SA, Glickman MS. Mycobacterium tuberculosis control host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med 2005;201:535-43.

  25. Rao V, Gao F, Chen B, Jacobs WR, Glickman MS. Trans-cyclopranation o mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis-induced inflammation and virulence. J Clin Invest 2006;116:1660-7.

  26. Mederos LM, Montoro EH, Valero-Guillén PL. Structural studies of cord factors from Mycobacterium simiae related to the capacity for tumour necrosis factor alpha (á-TNF) induction. Microbiology 2010;156:3744-53.

  27. McMurray DN. A coordinated strategy for evaluating new vaccines for human and animal tuberculosis. Tuberculosis 2001;81:141-6.

  28. Raj PP, Srivastava S, Jain SK, Srivastava BS, Srivastava R. Protection by live Mycobacterium´habana´ vaccine against Mycobacterium tuberculosis H37Rv challenge in mice. Indian J Med Res 2003;117:139-45.

  29. López B, Aguilar LD, Orozco H, Burger M, Espitia C, Ritacco V, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003;133:30-7.

  30. Valdés I, Montoro E, Aguilar D, Orozco H, Hernández-Pando R. Mycobacterium ´habana´: Virulence, Immunogenicity and protection against experimental tuberculosis. Int J Tuberc Lung Dis 2010;14(Suppl. 2):243.

  31. Ottenhoff TH, de Boer T, Verhagen CE, Verreck FA, van Dissel JT. Human deficiencies in type I cytokine receptors reveal the essential role of type I cytokines in immunity to intracellular bacteria. Microbes Infect 2000;2:1559-66.

  32. Van Ham SM, Samson JN, Bos NA, Damoiseaux J, Laman JD, Wauben MHM. Vaccination immunology: Prevention and beyond. Immunol Let 2009;122:101-3.

  33. Hernández-Pando R, Orozco EH, Sampieri A, Pavón L, Velasquillo C, Larriva SJ, et al. Correlation between the kinetics of Th1/Th2 cells and the pathology in a murine model of experimental pulmonary tuberculosis. Immunol 1996;89:26- 33.

  34. Jyothi MD, Garg SK, Singh NB. Mechanisms involved in protective immune response generated by secretory proteins of Mycobacterium´habana´ against experimental tuberculosis. Scand J Immunol 2000; 51:502-10.

  35. Singh NB, Srivastava K, Malaviya B, Kandpal H, Srivastava A, Gupta HP. The 65 kDa protein of Mycobacterium´habana´ and its putative role in immunity against experimental tuberculosis. Immunol Cell Biol 1995;73:372-6.

  36. Chaturvedi V, Srivastava A, Gupta HP, Srivastava BS. Protective antigens of Mycobacterium´habana´ are distributed between peripheral and integral compartments of plasma membrane: a study in experimental tuberculosis of mouse. Vaccine 1999;17:2882-7.

  37. Horwitz MAB, Lee WE, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995;92:1530-4.

  38. Haslov K, Andersen A, Nagai S, Gottshau A, Sorensen T, Andersen P. Guinea pig cellular immune response to protein secreted by Mycobacterium tuberculosis: association between levels of antibodies and Mycobacterium antigens. Infect Immun 1995;63:804-10.

  39. Chaturvedi V, Gupta HP. Evaluation of integral membrane antigens of Mycobacterium´habana´ for serodiagnosis of extrapulmonary tuberculosis: association between levels of antibodies and Mycobacterium tuberculosis antigens. FEMS Immunol Med Microbiol 2001;33:1-7.

  40. Collins FM, Watson SR. Immune response to atypical mycobacterial lung infections. Reviews Infect Dis 1981;3:981-9.

  41. Walker KB, Bar P, Brennan MJ, Ho MM, Eskola J, Thiry G, et al. The second Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine 2010;28:2259–70




2020     |     www.medigraphic.com